Serodus ApS will receive final pharmacological reports from last studies with SER130. Shareholder meeting will be held in Q1 2026. Read more here

Serodus ApS has initiated sale of SER150. Serodus ApS will finalize the pharmacological studies of SER130. Read more here

Draft report SER150 CL-009 was received and will be discussed with the Australian contract organisation and the Serodus biostatistician consultant. In March 2025 the company launched a Private Placement with…

Download investor letter here

Download the minutes here

Download notice here

Unblinding of the database after SER150 CL-009 was delayed. Calculation of SER150 effect on kidney function compared to placebo is consequently also delayed. Read more here

Contacts to banks for assisting Serodus in selling Serodus AS, the pipeline or the individual assets was initiated. Database for SER150 CL-009 is expected to be unblinded late August or…

Download the minutes here

Read more here